September 21, 2020 11:15 AM EDT

Israeli biotech raises $57M to go where current BRAF inhibitors can't, with backing from Novartis, SR One

Amber Tong

For the blockbuster potential of Novartis’ Tafinlar and Pfizer’s Braftovi, all the BRAF inhibitors on the market so far only target V600 mutations — which accounts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Israeli biotech raises $57M to go where current BRAF inhibitors can't, with backing from Novartis, SR One

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Biotech VC firm outlines plans for $100M fund

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Breaking down silos with a new quantitative approach to drug development

Is­raeli biotech rais­es $57M to go where cur­rent BRAF in­hibitors can't, with back­ing from No­var­tis, SR One

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Israeli biotech raises $57M to go where current BRAF inhibitors can't, with backing from Novartis, SR One